Alphamab Oncology (HK:9966) has released an update.
Alphamab Oncology has initiated a first-in-human Phase I clinical trial for JSKN016, its innovative bispecific antibody-drug conjugate aimed at treating advanced malignant solid tumors. The trial, conducted in China, will assess the safety, efficacy, and optimal dosing of the drug in up to 140 patients. This milestone underscores the company’s commitment to expanding its oncology pipeline and leveraging its proprietary biologics platform.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.
